Alnylam Pharmaceuticals (ALNY) Research & Development (2009 - 2026)
Alnylam Pharmaceuticals posted quarterly Research & Development of $364.9 million for Q1 2026, up 37.62% year-on-year from $265.1 million in Q1 2025, and down 1.98% on a QoQ basis from $372.2 million in Q4 2025.
Alnylam Pharmaceuticals (ALNY) has 18 years of Research & Development data on file, last reported at $364.9 million in Q1 2026.
- For the quarter ending Q1 2026, Research & Development rose 37.62% year-over-year to $364.9 million; the trailing twelve-month figure through Mar 2026 stood at $1.4 billion (up 25.58% YoY), and the FY2025 full-year result was $1.3 billion, up 17.19% from the prior year.
- Research & Development for Q1 2026 stood at $364.9 million, down from $372.2 million in the prior quarter.
- Across five years, Research & Development topped out at $372.2 million in Q4 2025 and bottomed at $169.9 million in Q1 2022.
- The 5-year median for Research & Development is $265.1 million (2025), against an average of $276.4 million.
- The widest annual swing landed in 2022, when Research & Development retreated 8.61%; it then surged 37.62% in 2026.
- A 5-year view of Research & Development shows it stood at $262.0 million in 2022, then advanced by 3.86% to $272.1 million in 2023, then grew by 10.3% to $300.2 million in 2024, then grew by 24.0% to $372.2 million in 2025, then slipped by 1.98% to $364.9 million in 2026.
- The last three Research & Development figures came in at $364.9 million (Q1 2026), $372.2 million (Q4 2025), and $358.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -2.30 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.54 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 364.87 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | 343.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 364.87 Mn |
| Dec 31, 2025 | 372.22 Mn |
| Sep 30, 2025 | 358.81 Mn |
| Jun 30, 2025 | 323.62 Mn |
| Mar 31, 2025 | 265.12 Mn |
| Dec 31, 2024 | 300.17 Mn |
| Sep 30, 2024 | 270.93 Mn |
| Jun 30, 2024 | 294.14 Mn |
| Mar 31, 2024 | 261.00 Mn |
| Dec 31, 2023 | 272.14 Mn |
| Sep 30, 2023 | 253.18 Mn |
| Jun 30, 2023 | 248.53 Mn |
| Mar 31, 2023 | 230.57 Mn |
| Dec 31, 2022 | 262.04 Mn |
| Sep 30, 2022 | 245.37 Mn |
| Jun 30, 2022 | 205.71 Mn |
| Mar 31, 2022 | 169.89 Mn |
| Dec 31, 2021 | 229.05 Mn |
| Sep 30, 2021 | 194.57 Mn |
| Jun 30, 2021 | 182.64 Mn |
| Mar 31, 2021 | 185.90 Mn |
| Dec 31, 2020 | 168.47 Mn |
| Sep 30, 2020 | 161.78 Mn |
| Jun 30, 2020 | 155.00 Mn |
| Mar 31, 2020 | 169.57 Mn |
| Dec 31, 2019 | 201.30 Mn |
| Sep 30, 2019 | 160.80 Mn |
| Jun 30, 2019 | 163.89 Mn |
| Mar 31, 2019 | 129.13 Mn |
| Dec 31, 2018 | 131.04 Mn |
| Sep 30, 2018 | 139.95 Mn |
| Jun 30, 2018 | 137.58 Mn |
| Mar 31, 2018 | 96.86 Mn |
| Dec 31, 2017 | 117.77 Mn |
| Sep 30, 2017 | 95.25 Mn |
| Jun 30, 2017 | 90.63 Mn |
| Mar 31, 2017 | 86.98 Mn |
| Dec 31, 2016 | 105.01 Mn |
| Sep 30, 2016 | 97.94 Mn |
| Jun 30, 2016 | 83.17 Mn |
| Mar 31, 2016 | 96.27 Mn |
| Dec 31, 2015 | 82.84 Mn |
| Sep 30, 2015 | 68.62 Mn |
| Jun 30, 2015 | 67.01 Mn |
| Mar 31, 2015 | 58.04 Mn |
| Dec 31, 2014 | 55.55 Mn |
| Sep 30, 2014 | 46.27 Mn |
| Jun 30, 2014 | 44.67 Mn |
| Mar 31, 2014 | 43.76 Mn |
| Dec 31, 2013 | 32.11 Mn |
| Sep 30, 2013 | 34.46 Mn |
| Jun 30, 2013 | 24.22 Mn |
| Mar 31, 2013 | 22.18 Mn |
| Dec 31, 2012 | 21.68 Mn |
| Sep 30, 2012 | 22.09 Mn |
| Jun 30, 2012 | 21.72 Mn |
| Mar 31, 2012 | 21.07 Mn |
| Dec 31, 2011 | 23.37 Mn |
| Sep 30, 2011 | 24.27 Mn |
| Jun 30, 2011 | 25.30 Mn |
| Mar 31, 2011 | 26.35 Mn |
| Dec 31, 2010 | 26.08 Mn |
| Sep 30, 2010 | 27.47 Mn |
| Jun 30, 2010 | 28.14 Mn |
| Mar 31, 2010 | 24.70 Mn |
| Dec 31, 2009 | 21.58 Mn |
| Sep 30, 2009 | 23.22 Mn |
| Jun 30, 2009 | 38.62 Mn |